Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6624202 | 0.90 | CACNA1C (0.34) | CACNA1CESR1PTGS1PDE4A | |
| SCHEMBL6624702 | 0.89 | CACNA1C (0.34) | CACNA1CKDM4ELMNAESR1PTGS1 | |
| SCHEMBL6643195 | 0.89 | CACNA1C (0.31) | CACNA1C | |
| SCHEMBL6623331 | 0.83 | CACNA1C (0.34) | CACNA1CKDM4ELMNAESR1PTGS1 | |
| SCHEMBL6624812 | 0.83 | CACNA1C (0.34) | CACNA1CKDM4ELMNAESR1PTGS1 | |
| SCHEMBL7734325 | 0.83 | ABCC2 (0.34) | — | |
| SCHEMBL6773445 | 0.83 | CACNA1C (0.34) | CACNA1CESR1PTGS1PDE4A | |
| SCHEMBL6895309 | 0.82 | ESR1 (0.33) | CACNA1CESR1PTGS1PDE4A | |
| SCHEMBL6886152 | 0.82 | ESR1 (0.33) | CACNA1CESR1PTGS1PDE4A | |
| SCHEMBL6887295 | 0.81 | ESR1 (0.34) | CACNA1CESR1PTGS1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1251133-B1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-6680313-B2 | 1-HYDROXYETHYL-2(IMIDAZO(5,1B)THIAZOL-2-YL-1-CARBAPEN-2-EM-3-C CARBOXYLIC ACID OR SALT, EXCELLENT ANTIBIOTIC ACTIVITY AGAINST A WIDE SPECTRUM OF BACTERIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-20 | — | — | US | disclosed |
| US-20030027809-A1 | Novel carbapenum derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
| EP-1251133-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027809-A1 | Novel carbapenum derivatives | DHPS, DPEP1, OXA1L | CACNA1C 3676/4885KDM4E 720/4885LMNA 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.